What Is HER2-Positive Colon Cancer? How Is It Treated?

HER2 is a protein receptor on the cell surface and a mediator of cell growth signals. It is encoded by the HER2 gene. The HER2 gene is a proto-oncogene, also known as Erbb2 or ERBB2.
HER2-related alterations are known to play a driving role in various cancers. This gene and receptor are among the most extensively studied molecular targets in cancer to date.
In HER2 + tumors, cancer cells produce too much of this receptor, leading to more aggressive cancer behavior. Before HER2 receptor-targeting new-generation targeted drugs were developed, HER2 positivity was associated with a poor disease course and more frequent recurrence. Approximately 20% of breast cancers are HER2-positive.
HER2 positivity is not a single phenomenon; it may involve overexpression, amplification or mutation. Overproduction of the HER2 gene (overexpression) or increased gene copies (amplification) is an important biomarker, particularly in breast cancer. Many HER2-targeted drugs are currently used, mainly in breast cancer and then in stomach cancer. However, studies show that mutations in the HER2 gene are molecular alterations as noteworthy and targetable as overproduction or amplification. All 3 changes in the HER2 gene—overexpression, amplification or mutation—can stimulate cell growth and proliferation; nevertheless, the 3 different conditions require different inhibitory drugs.

Targeting HER2 in Colon and Rectal Cancers
HER2 is generally overexpressed on the cell surface in colorectal cancers in approximately 3-5% of cases and in RAS/BRAF-wild-type (without mutations) colorectal tumors in 5-14% of cases. Treatment approaches for tumors with HER2 overexpression include trastuzumab plus lapatinib and trastuzumab plus pertuzumab.
In a phase 2 clinical trial, 27 heavily pretreated patients with HER2-positive metastatic colon cancer responded well to a dual targeted-drug regimen containing no chemotherapy, commonly used to treat HER2-positive breast cancer. The 27 patients included in this study were identified by screening for KRAS exon 2 (codon 12 and 13) mutation-negative metastatic colorectal cancer among 914 patients.
Most patients had extensive metastatic disease and distal (end-section) colon tumors. Nearly 75% had previously received at least four lines of treatment, and the median total duration of prior treatments was around 20 months.
Study Results
- Patients were treated with a combination of trastuzumab and lapatinib.
- At 1 year, 12 of 27 patients (45%) were still alive.
- At a median follow-up of 94 weeks, one patient (4%) had a complete response, seven (26%) had a partial response, and disease stabilized in 12 patients (44%).
Conclusion
Patients with advanced colorectal cancer should also be tested for HER2 overexpression, because HER2 is a molecular target that should not be overlooked in colorectal cancers, and the currently available HER2-targeted drugs appear effective in this tumor type.
Sources
2. Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Apr 20.
3. André T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, Yoshino T, et al. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Curr Colorectal Cancer Rep. 2013. 9:261-269.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.